Kallikrein-related peptidases (KLKs) and the hallmarks of cancer

Panagiota S. Filippou, George S. Karagiannis, Natasha Musrap, Eleftherios P. Diamandis

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Abstract: The kallikrein-related peptidases (KLKs) represent the largest family of serine proteases within the human genome and are expressed in various tissues. Although they regulate several important physiological functions, KLKs have also been implicated in numerous pathophysiological processes, including cancer. Growing evidence describing the deregulation of KLK expression and secretion, as well as activation in various malignancies, has uncovered their potential as mediators of cancer progression, biomarkers of disease and as candidate therapeutic targets. The diversity of signalling pathways and proteolytic cascades involving KLKs and their downstream targets appears to affect cancer biology through multiple mechanisms, including those related to the hallmarks of cancer. The aim of this review is to provide an update on the importance of KLK-driven molecular pathways in relation to cancer cell traits associated with the hallmarks of cancer and to highlight their potential in personalized therapeutics.

Original languageEnglish
Pages (from-to)277-291
Number of pages15
JournalCritical Reviews in Clinical Laboratory Sciences
Volume53
Issue number4
DOIs
Publication statusPublished - 3 Jul 2016

Fingerprint

Kallikreins
Deregulation
Serine Proteases
Peptide Hydrolases
Genes
Chemical activation
Cells
Tissue
Neoplasms
Human Genome
Tumor Biomarkers
Disease Progression
Therapeutics

Cite this

Filippou, Panagiota S. ; Karagiannis, George S. ; Musrap, Natasha ; Diamandis, Eleftherios P. / Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. In: Critical Reviews in Clinical Laboratory Sciences. 2016 ; Vol. 53, No. 4. pp. 277-291.
@article{c9549102dccd469a965e6a7ce7b8d8c3,
title = "Kallikrein-related peptidases (KLKs) and the hallmarks of cancer",
abstract = "Abstract: The kallikrein-related peptidases (KLKs) represent the largest family of serine proteases within the human genome and are expressed in various tissues. Although they regulate several important physiological functions, KLKs have also been implicated in numerous pathophysiological processes, including cancer. Growing evidence describing the deregulation of KLK expression and secretion, as well as activation in various malignancies, has uncovered their potential as mediators of cancer progression, biomarkers of disease and as candidate therapeutic targets. The diversity of signalling pathways and proteolytic cascades involving KLKs and their downstream targets appears to affect cancer biology through multiple mechanisms, including those related to the hallmarks of cancer. The aim of this review is to provide an update on the importance of KLK-driven molecular pathways in relation to cancer cell traits associated with the hallmarks of cancer and to highlight their potential in personalized therapeutics.",
author = "Filippou, {Panagiota S.} and Karagiannis, {George S.} and Natasha Musrap and Diamandis, {Eleftherios P.}",
year = "2016",
month = "7",
day = "3",
doi = "10.3109/10408363.2016.1154643",
language = "English",
volume = "53",
pages = "277--291",
journal = "Critical Reviews in Clinical Laboratory Sciences",
issn = "1040-8363",
publisher = "Informa Healthcare",
number = "4",

}

Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. / Filippou, Panagiota S.; Karagiannis, George S.; Musrap, Natasha; Diamandis, Eleftherios P.

In: Critical Reviews in Clinical Laboratory Sciences, Vol. 53, No. 4, 03.07.2016, p. 277-291.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Kallikrein-related peptidases (KLKs) and the hallmarks of cancer

AU - Filippou, Panagiota S.

AU - Karagiannis, George S.

AU - Musrap, Natasha

AU - Diamandis, Eleftherios P.

PY - 2016/7/3

Y1 - 2016/7/3

N2 - Abstract: The kallikrein-related peptidases (KLKs) represent the largest family of serine proteases within the human genome and are expressed in various tissues. Although they regulate several important physiological functions, KLKs have also been implicated in numerous pathophysiological processes, including cancer. Growing evidence describing the deregulation of KLK expression and secretion, as well as activation in various malignancies, has uncovered their potential as mediators of cancer progression, biomarkers of disease and as candidate therapeutic targets. The diversity of signalling pathways and proteolytic cascades involving KLKs and their downstream targets appears to affect cancer biology through multiple mechanisms, including those related to the hallmarks of cancer. The aim of this review is to provide an update on the importance of KLK-driven molecular pathways in relation to cancer cell traits associated with the hallmarks of cancer and to highlight their potential in personalized therapeutics.

AB - Abstract: The kallikrein-related peptidases (KLKs) represent the largest family of serine proteases within the human genome and are expressed in various tissues. Although they regulate several important physiological functions, KLKs have also been implicated in numerous pathophysiological processes, including cancer. Growing evidence describing the deregulation of KLK expression and secretion, as well as activation in various malignancies, has uncovered their potential as mediators of cancer progression, biomarkers of disease and as candidate therapeutic targets. The diversity of signalling pathways and proteolytic cascades involving KLKs and their downstream targets appears to affect cancer biology through multiple mechanisms, including those related to the hallmarks of cancer. The aim of this review is to provide an update on the importance of KLK-driven molecular pathways in relation to cancer cell traits associated with the hallmarks of cancer and to highlight their potential in personalized therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84965006399&partnerID=8YFLogxK

U2 - 10.3109/10408363.2016.1154643

DO - 10.3109/10408363.2016.1154643

M3 - Review article

C2 - 26886390

AN - SCOPUS:84965006399

VL - 53

SP - 277

EP - 291

JO - Critical Reviews in Clinical Laboratory Sciences

JF - Critical Reviews in Clinical Laboratory Sciences

SN - 1040-8363

IS - 4

ER -